GJB2_HUMAN,W77R,0.945,Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Helix (Pr = 0.27 | P = 0.04); Loss of Strand (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.25 | P = 0.01); Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000012|ELME000106|ELME000149|ELME000233,-
GJB2_HUMAN,R127C,0.492,-,-,-
GJB2_HUMAN,R127L,0.593,Altered DNA binding (Pr = 0.34 | P = 1.1e-03); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Altered Coiled coil (Pr = 0.12 | P = 0.04), ELME000051|ELME000052|ELME000106|ELME000333,-
GJB2_HUMAN,R127H,0.335,-,-,-
GJB2_HUMAN,I121N,0.508,Gain of Intrinsic disorder (Pr = 0.38 | P = 0.01); Gain of B-factor (Pr = 0.24 | P = 0.04); Loss of Acetylation at K116 (Pr = 0.23 | P = 0.02); Altered DNA binding (Pr = 0.21 | P = 0.02); Altered Coiled coil (Pr = 0.13 | P = 0.04); Altered Transmembrane protein (Pr = 0.12 | P = 0.03); Altered Stability (Pr = 0.09 | P = 0.05); Gain of N-linked glycosylation at I121 (Pr = 0.06 | P = 0.02); Gain of GPI-anchor amidation at I121 (Pr = 0.02 | P = 0.02), ELME000052|ELME000070|ELME000202|PS00001,-
GJB2_HUMAN,L81R,0.908,Gain of Strand (Pr = 0.29 | P = 4.9e-03); Altered Ordered interface (Pr = 0.25 | P = 0.03), ELME000155|ELME000333,-
GJB2_HUMAN,L81V,0.588,Loss of Helix (Pr = 0.28 | P = 0.03); Gain of Strand (Pr = 0.28 | P = 9.7e-03); Altered Ordered interface (Pr = 0.25 | P = 0.02), ELME000155|ELME000333,-
GJB2_HUMAN,G200A,0.426,-,-,-
GJB2_HUMAN,D46E,0.852,Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.25 | P = 1.1e-03); Altered Metal binding (Pr = 0.23 | P = 0.04); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.6e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.05), None,-
GJB2_HUMAN,D46N,0.868,Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.26 | P = 9.4e-04); Altered Metal binding (Pr = 0.24 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.2e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.04), PS00008,-
GJB2_HUMAN,G45R,0.876,Altered Ordered interface (Pr = 0.36 | P = 3.3e-03); Altered Transmembrane protein (Pr = 0.34 | P = 3.4e-05); Loss of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Altered Metal binding (Pr = 0.12 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.5e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.04), None,-
GJB2_HUMAN,G45E,0.902,Altered Ordered interface (Pr = 0.35 | P = 4.0e-03); Altered Metal binding (Pr = 0.32 | P = 0.01); Gain of Relative solvent accessibility (Pr = 0.31 | P = 6.2e-03); Altered Transmembrane protein (Pr = 0.26 | P = 7.2e-04); Gain of Pyrrolidone carboxylic acid at Q48 (Pr = 0.14 | P = 5.6e-03); Gain of Catalytic site at E47 (Pr = 0.10 | P = 0.04), None,-
GJB2_HUMAN,I82N,0.896,Loss of Strand (Pr = 0.26 | P = 0.03); Altered Ordered interface (Pr = 0.24 | P = 0.03); Altered Stability (Pr = 0.19 | P = 0.01), ELME000155|ELME000333,-
GJB2_HUMAN,I82M,0.568,Gain of Helix (Pr = 0.27 | P = 0.04); Loss of Strand (Pr = 0.27 | P = 0.01); Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Stability (Pr = 0.09 | P = 0.05), ELME000155|ELME000333|ELME000336,-
GJB2_HUMAN,M151R,0.829,Altered Ordered interface (Pr = 0.29 | P = 3.6e-03); Loss of Helix (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.27 | P = 7.8e-04); Gain of Sulfation at Y152 (Pr = 0.01 | P = 0.05), ELME000146|ELME000328,-
GJB2_HUMAN,P70S,0.876,Altered Metal binding (Pr = 0.30 | P = 0.02); Altered Ordered interface (Pr = 0.29 | P = 5.5e-03); Altered Transmembrane protein (Pr = 0.27 | P = 9.5e-04), ELME000120|ELME000182|ELME000336,-
GJB2_HUMAN,P70R,0.925,Altered Ordered interface (Pr = 0.32 | P = 0.01); Altered Metal binding (Pr = 0.30 | P = 4.1e-03); Altered Transmembrane protein (Pr = 0.26 | P = 1.0e-03), ELME000062|ELME000120|ELME000182|ELME000336,-
GJB2_HUMAN,P70L,0.904,Altered Ordered interface (Pr = 0.36 | P = 3.5e-03); Altered Transmembrane protein (Pr = 0.32 | P = 7.8e-05); Altered Metal binding (Pr = 0.30 | P = 4.4e-03), ELME000120|ELME000149|ELME000182|ELME000317|ELME000336,-
GJB2_HUMAN,P70A,0.845,Altered Ordered interface (Pr = 0.35 | P = 5.8e-03); Altered Transmembrane protein (Pr = 0.28 | P = 4.6e-04); Altered Metal binding (Pr = 0.26 | P = 7.9e-03), ELME000120|ELME000182|ELME000336,-
GJB2_HUMAN,P175T,0.875,Altered Metal binding (Pr = 0.26 | P = 0.03); Altered Transmembrane protein (Pr = 0.26 | P = 9.5e-04); Gain of Disulfide linkage at C174 (Pr = 0.26 | P = 3.1e-03); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03), ELME000052|PS00408,-
GJB2_HUMAN,P175H,0.905,Altered Metal binding (Pr = 0.39 | P = 8.5e-03); Altered Ordered interface (Pr = 0.31 | P = 0.02); Gain of Disulfide linkage at C174 (Pr = 0.26 | P = 3.2e-03); Altered Transmembrane protein (Pr = 0.24 | P = 1.7e-03); Loss of Relative solvent accessibility (Pr = 0.23 | P = 0.05), PS00408,-
GJB2_HUMAN,A78T,0.515,Altered Ordered interface (Pr = 0.27 | P = 0.05); Gain of Strand (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.24 | P = 0.01), ELME000052|ELME000173|ELME000334|ELME000335,-
GJB2_HUMAN,A78S,0.394,-,-,-
GJB2_HUMAN,Y158C,0.840,Altered Transmembrane protein (Pr = 0.48 | P = 0.0e+00); Altered Ordered interface (Pr = 0.40 | P = 1.0e-03); Gain of Helix (Pr = 0.27 | P = 0.05); Loss of Sulfation at Y158 (Pr = 0.01 | P = 0.05), ELME000120,-
GJB2_HUMAN,S199F,0.894,Altered Transmembrane protein (Pr = 0.01 | P = 0.01), ELME000085|ELME000148,-
GJB2_HUMAN,R32S,0.936,Altered Ordered interface (Pr = 0.26 | P = 0.01); Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000148|ELME000149|ELME000335|ELME000336,-
GJB2_HUMAN,R32C,0.937,Loss of Strand (Pr = 0.27 | P = 0.02); Altered Ordered interface (Pr = 0.26 | P = 0.02); Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000148|ELME000149,-
GJB2_HUMAN,R32G,0.948,Loss of Helix (Pr = 0.28 | P = 0.02); Altered Ordered interface (Pr = 0.27 | P = 0.01); Gain of Strand (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000148|ELME000149,-
GJB2_HUMAN,R32L,0.946,Loss of Strand (Pr = 0.33 | P = 3.5e-04); Gain of Helix (Pr = 0.30 | P = 7.2e-03); Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000148|ELME000149,-
GJB2_HUMAN,R32H,0.899,Loss of Helix (Pr = 0.27 | P = 0.05); Altered Ordered interface (Pr = 0.24 | P = 0.04); Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000148|ELME000149,-
GJB2_HUMAN,Q80P,0.936,Altered Ordered interface (Pr = 0.29 | P = 0.03); Loss of Strand (Pr = 0.26 | P = 0.05), ELME000237,-
GJB2_HUMAN,Q80K,0.835,Loss of Strand (Pr = 0.27 | P = 0.03); Altered Ordered interface (Pr = 0.25 | P = 0.02), ELME000137|ELME000146|ELME000313,-
GJB2_HUMAN,Q80H,0.828,Altered Ordered interface (Pr = 0.26 | P = 0.01), None,-
GJB2_HUMAN,Q80L,0.902,Loss of Strand (Pr = 0.30 | P = 2.1e-03); Altered Ordered interface (Pr = 0.29 | P = 0.03); Gain of Helix (Pr = 0.28 | P = 0.02), ELME000045|ELME000149,-
GJB2_HUMAN,Q80R,0.851,Gain of Helix (Pr = 0.28 | P = 0.02); Loss of Strand (Pr = 0.27 | P = 0.02); Altered Ordered interface (Pr = 0.24 | P = 0.03), ELME000137|ELME000146|ELME000313,-
GJB2_HUMAN,Q7P,0.502,Altered Transmembrane protein (Pr = 0.27 | P = 5.9e-04); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.19 | P = 0.04), PS00008,-
GJB2_HUMAN,Q7H,0.138,-,-,-
GJB2_HUMAN,I20M,0.379,-,-,-
GJB2_HUMAN,I20T,0.623,Altered Stability (Pr = 0.51 | P = 1.6e-03); Gain of Intrinsic disorder (Pr = 0.30 | P = 0.05); Altered Transmembrane protein (Pr = 0.24 | P = 1.4e-03); Loss of Catalytic site at K22 (Pr = 0.15 | P = 0.02); Altered Metal binding (Pr = 0.04 | P = 0.05), ELME000052|ELME000063|PS00005,-
GJB2_HUMAN,I20F,0.617,Altered Transmembrane protein (Pr = 0.27 | P = 7.1e-04); Loss of Catalytic site at K22 (Pr = 0.16 | P = 0.02), ELME000184|ELME000197|ELME000198|ELME000328,-
GJB2_HUMAN,V43G,0.911,Altered Stability (Pr = 0.38 | P = 3.2e-03); Altered Transmembrane protein (Pr = 0.31 | P = 1.3e-04); Gain of Relative solvent accessibility (Pr = 0.31 | P = 6.8e-03); Altered Ordered interface (Pr = 0.28 | P = 0.03); Altered Metal binding (Pr = 0.13 | P = 0.05); Gain of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.2e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.05), None,-
GJB2_HUMAN,V43L,0.795,Altered Transmembrane protein (Pr = 0.28 | P = 6.0e-04); Loss of Strand (Pr = 0.28 | P = 9.9e-03); Gain of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Altered Metal binding (Pr = 0.12 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.1e-03); Gain of Catalytic site at E47 (Pr = 0.09 | P = 0.04), None,-
GJB2_HUMAN,V43M,0.789,Gain of Relative solvent accessibility (Pr = 0.28 | P = 0.01); Loss of Strand (Pr = 0.26 | P = 0.03); Altered Transmembrane protein (Pr = 0.25 | P = 1.3e-03); Altered Metal binding (Pr = 0.14 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 6.9e-03); Gain of Catalytic site at E47 (Pr = 0.09 | P = 0.04), None,-
GJB2_HUMAN,W44C,0.959,Altered Metal binding (Pr = 0.44 | P = 6.9e-03); Loss of Relative solvent accessibility (Pr = 0.33 | P = 3.5e-03); Altered Transmembrane protein (Pr = 0.28 | P = 4.4e-04); Altered Ordered interface (Pr = 0.28 | P = 0.04); Loss of Strand (Pr = 0.26 | P = 0.03); Gain of Disulfide linkage at W44 (Pr = 0.12 | P = 0.04); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.3e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.05), None,-
GJB2_HUMAN,W44L,0.908,Loss of Relative solvent accessibility (Pr = 0.30 | P = 0.01); Loss of Strand (Pr = 0.29 | P = 5.3e-03); Altered Transmembrane protein (Pr = 0.26 | P = 9.0e-04); Altered Metal binding (Pr = 0.13 | P = 0.05); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.2e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.05); Gain of Methylation at K41 (Pr = 0.09 | P = 0.04), ELME000146,-
GJB2_HUMAN,W44S,0.952,Gain of Relative solvent accessibility (Pr = 0.38 | P = 6.1e-04); Altered Ordered interface (Pr = 0.35 | P = 3.9e-03); Altered Transmembrane protein (Pr = 0.31 | P = 1.1e-04); Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Altered Metal binding (Pr = 0.26 | P = 0.03); Gain of Ubiquitylation at K41 (Pr = 0.17 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.0e-03); Gain of Catalytic site at E47 (Pr = 0.11 | P = 0.04); Gain of Methylation at K41 (Pr = 0.11 | P = 0.03), ELME000064|ELME000085|PS00006,-
GJB2_HUMAN,W44G,0.940,Gain of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered Ordered interface (Pr = 0.27 | P = 0.04); Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03); Gain of B-factor (Pr = 0.26 | P = 0.02); Gain of Ubiquitylation at K41 (Pr = 0.17 | P = 0.03); Altered Metal binding (Pr = 0.13 | P = 0.05); Gain of Methylation at K41 (Pr = 0.12 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.4e-03); Gain of Catalytic site at E47 (Pr = 0.10 | P = 0.04), None,-
GJB2_HUMAN,F31I,0.920,Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000148,-
GJB2_HUMAN,W133S,0.898,Altered DNA binding (Pr = 0.31 | P = 1.3e-03); Altered Ordered interface (Pr = 0.29 | P = 5.0e-03); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Gain of Catalytic site at Y136 (Pr = 0.09 | P = 0.05), ELME000051|ELME000053|ELME000147|ELME000336,-
GJB2_HUMAN,W133G,0.892,Altered Ordered interface (Pr = 0.31 | P = 0.01); Altered DNA binding (Pr = 0.27 | P = 3.6e-03); Altered Stability (Pr = 0.14 | P = 0.02); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Loss of Catalytic site at Y136 (Pr = 0.08 | P = 0.05), ELME000051|ELME000053|ELME000147|ELME000336,-
GJB2_HUMAN,H100P,0.638,Loss of Helix (Pr = 0.28 | P = 0.03); Gain of B-factor (Pr = 0.25 | P = 0.03); Gain of Allosteric site at Y97 (Pr = 0.22 | P = 0.03); Altered Disordered interface (Pr = 0.18 | P = 0.05); Altered Coiled coil (Pr = 0.14 | P = 0.03), ELME000102|ELME000103|ELME000108|ELME000271,-
GJB2_HUMAN,H100Q,0.377,-,-,-
GJB2_HUMAN,H100Y,0.421,-,-,-
GJB2_HUMAN,L79P,0.933,Altered Ordered interface (Pr = 0.36 | P = 2.7e-03); Loss of Helix (Pr = 0.28 | P = 0.03); Gain of Strand (Pr = 0.28 | P = 7.2e-03); Gain of Allosteric site at W77 (Pr = 0.20 | P = 0.04); Altered Stability (Pr = 0.16 | P = 0.02), None,-
GJB2_HUMAN,L79V,0.647,Loss of Helix (Pr = 0.28 | P = 0.03); Gain of Strand (Pr = 0.28 | P = 1.0e-02); Altered Ordered interface (Pr = 0.25 | P = 0.02), None,-
GJB2_HUMAN,K105R,0.099,-,-,-
GJB2_HUMAN,N54S,0.847,Altered Metal binding (Pr = 0.29 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03); Loss of Disulfide linkage at C53 (Pr = 0.26 | P = 4.8e-03); Loss of Pyrrolidone carboxylic acid at Q57 (Pr = 0.11 | P = 8.3e-03), ELME000336|PS00407,-
GJB2_HUMAN,N54K,0.928,Altered Metal binding (Pr = 0.32 | P = 0.01); Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Altered Ordered interface (Pr = 0.30 | P = 0.03); Loss of Disulfide linkage at C53 (Pr = 0.27 | P = 3.3e-03); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Gain of Pyrrolidone carboxylic acid at Q57 (Pr = 0.12 | P = 7.7e-03), ELME000106|PS00407,-
GJB2_HUMAN,N54H,0.894,Altered Metal binding (Pr = 0.57 | P = 3.3e-03); Loss of Relative solvent accessibility (Pr = 0.33 | P = 3.5e-03); Altered Ordered interface (Pr = 0.31 | P = 0.02); Altered Transmembrane protein (Pr = 0.29 | P = 2.5e-04); Loss of Disulfide linkage at C53 (Pr = 0.27 | P = 2.6e-03); Loss of Pyrrolidone carboxylic acid at Q57 (Pr = 0.12 | P = 8.1e-03), PS00407,-
GJB2_HUMAN,V198M,0.475,-,-,-
GJB2_HUMAN,G130V,0.935,Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered DNA binding (Pr = 0.28 | P = 5.0e-03); Altered Transmembrane protein (Pr = 0.16 | P = 0.01); Altered Coiled coil (Pr = 0.08 | P = 0.05), ELME000051|ELME000053|ELME000147|ELME000233,-
GJB2_HUMAN,G130D,0.933,Altered Coiled coil (Pr = 0.41 | P = 6.7e-03); Altered Ordered interface (Pr = 0.28 | P = 0.04); Gain of Helix (Pr = 0.28 | P = 0.03); Loss of Strand (Pr = 0.28 | P = 0.01); Altered DNA binding (Pr = 0.27 | P = 4.3e-03); Altered Metal binding (Pr = 0.19 | P = 0.04); Altered Transmembrane protein (Pr = 0.17 | P = 1.0e-02), ELME000051|ELME000053|ELME000147,-
GJB2_HUMAN,V38A,0.740,Gain of Helix (Pr = 0.29 | P = 0.01); Loss of Strand (Pr = 0.29 | P = 3.7e-03); Altered Transmembrane protein (Pr = 0.28 | P = 5.4e-04); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02), ELME000148,-
GJB2_HUMAN,V37L,0.739,Loss of Strand (Pr = 0.31 | P = 1.0e-03); Gain of Helix (Pr = 0.30 | P = 8.5e-03); Gain of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered Transmembrane protein (Pr = 0.26 | P = 1.0e-03), ELME000148|ELME000149,-
GJB2_HUMAN,V37I,0.503,Loss of Strand (Pr = 0.26 | P = 0.03); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Altered Transmembrane protein (Pr = 0.24 | P = 1.5e-03), ELME000148|ELME000149,-
GJB2_HUMAN,D66H,0.940,Altered Metal binding (Pr = 0.58 | P = 7.8e-04); Altered Transmembrane protein (Pr = 0.35 | P = 2.4e-05); Altered Ordered interface (Pr = 0.30 | P = 3.1e-03); Loss of Relative solvent accessibility (Pr = 0.30 | P = 0.01); Loss of Disulfide linkage at C64 (Pr = 0.17 | P = 0.03), PS00407,-
GJB2_HUMAN,V84M,0.669,Loss of Strand (Pr = 0.27 | P = 0.02), ELME000052|ELME000136|ELME000155|ELME000159|ELME000333|ELME000358,-
GJB2_HUMAN,V84L,0.663,Loss of Strand (Pr = 0.30 | P = 2.1e-03); Gain of Helix (Pr = 0.28 | P = 0.03), ELME000052|ELME000136|ELME000155|ELME000159|ELME000333|ELME000358,-
GJB2_HUMAN,V84A,0.761,Loss of Strand (Pr = 0.28 | P = 8.2e-03), ELME000052|ELME000136|ELME000155|ELME000159|ELME000333|ELME000358,-
GJB2_HUMAN,K15T,0.560,Loss of Relative solvent accessibility (Pr = 0.30 | P = 8.5e-03); Altered Transmembrane protein (Pr = 0.26 | P = 1.0e-03); Altered Metal binding (Pr = 0.05 | P = 0.04), ELME000053|PS00008,-
GJB2_HUMAN,L214P,0.630,Altered Ordered interface (Pr = 0.30 | P = 2.7e-03), ELME000020|ELME000045|ELME000081|ELME000120|ELME000149|ELME000182,-
GJB2_HUMAN,L214M,0.119,-,-,-
GJB2_HUMAN,E120K,0.307,-,-,-
GJB2_HUMAN,V95M,0.531,Loss of Allosteric site at H94 (Pr = 0.22 | P = 0.03); Altered Coiled coil (Pr = 0.18 | P = 0.02); Altered Metal binding (Pr = 0.07 | P = 0.02), None,-
GJB2_HUMAN,G59R,0.951,Altered Ordered interface (Pr = 0.31 | P = 0.01); Altered Transmembrane protein (Pr = 0.29 | P = 4.0e-04); Loss of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Altered Metal binding (Pr = 0.20 | P = 0.03); Loss of Disulfide linkage at C60 (Pr = 0.19 | P = 0.02); Loss of Catalytic site at C60 (Pr = 0.15 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q57 (Pr = 0.11 | P = 8.5e-03), PS00407,-
GJB2_HUMAN,G59V,0.958,Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Altered Ordered interface (Pr = 0.29 | P = 0.02); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.20 | P = 0.03); Loss of Disulfide linkage at C60 (Pr = 0.20 | P = 0.02); Loss of Catalytic site at C60 (Pr = 0.16 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q57 (Pr = 0.14 | P = 5.6e-03), PS00407,-
GJB2_HUMAN,G59A,0.912,Loss of Relative solvent accessibility (Pr = 0.28 | P = 0.02); Altered Ordered interface (Pr = 0.27 | P = 0.05); Altered Transmembrane protein (Pr = 0.23 | P = 2.7e-03); Gain of Disulfide linkage at C60 (Pr = 0.20 | P = 0.02); Altered Metal binding (Pr = 0.19 | P = 0.03); Loss of Catalytic site at C60 (Pr = 0.15 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q57 (Pr = 0.11 | P = 8.0e-03), PS00407,-
GJB2_HUMAN,G59S,0.907,Altered Ordered interface (Pr = 0.31 | P = 0.01); Gain of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered Transmembrane protein (Pr = 0.26 | P = 1.2e-03); Gain of Disulfide linkage at C60 (Pr = 0.20 | P = 0.02); Altered Metal binding (Pr = 0.19 | P = 0.03); Gain of Catalytic site at C60 (Pr = 0.16 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q57 (Pr = 0.11 | P = 8.7e-03), ELME000053|ELME000162|PS00005|PS00407,-
GJB2_HUMAN,R184Q,0.866,Altered Transmembrane protein (Pr = 0.33 | P = 4.9e-05); Loss of Strand (Pr = 0.26 | P = 0.05); Loss of Allosteric site at R184 (Pr = 0.24 | P = 0.02); Altered Metal binding (Pr = 0.14 | P = 0.04); Loss of Disulfide linkage at C180 (Pr = 0.13 | P = 0.04), ELME000062|ELME000063|ELME000155|ELME000202|PS00408,-
GJB2_HUMAN,R184W,0.918,Altered Ordered interface (Pr = 0.29 | P = 0.04); Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03); Loss of Allosteric site at R184 (Pr = 0.22 | P = 0.03); Loss of Disulfide linkage at C180 (Pr = 0.14 | P = 0.04); Altered Metal binding (Pr = 0.10 | P = 0.05), ELME000062|ELME000063|ELME000155|PS00408,-
GJB2_HUMAN,R184G,0.945,Altered Ordered interface (Pr = 0.33 | P = 8.1e-03); Altered Transmembrane protein (Pr = 0.28 | P = 6.5e-04); Loss of Allosteric site at R184 (Pr = 0.26 | P = 0.01); Loss of Disulfide linkage at C180 (Pr = 0.13 | P = 0.04); Altered Metal binding (Pr = 0.10 | P = 0.05); Gain of Methylation at K188 (Pr = 0.10 | P = 0.04), ELME000062|ELME000063|ELME000085|ELME000155|PS00408,-
GJB2_HUMAN,R184P,0.968,Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Transmembrane protein (Pr = 0.28 | P = 4.2e-04); Loss of Strand (Pr = 0.27 | P = 0.01); Loss of Allosteric site at R184 (Pr = 0.26 | P = 0.01); Gain of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Altered Metal binding (Pr = 0.13 | P = 0.05); Loss of Disulfide linkage at C180 (Pr = 0.13 | P = 0.04); Gain of Methylation at K188 (Pr = 0.10 | P = 0.04), ELME000062|ELME000063|ELME000136|ELME000155|ELME000159|PS00408,-
GJB2_HUMAN,C53Y,0.947,Loss of Disulfide linkage at C53 (Pr = 0.38 | P = 6.1e-04); Altered Metal binding (Pr = 0.37 | P = 7.8e-03); Altered Transmembrane protein (Pr = 0.32 | P = 1.0e-04); Altered Ordered interface (Pr = 0.32 | P = 8.4e-03); Gain of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.6e-03); Gain of Catalytic site at C53 (Pr = 0.08 | P = 0.05), ELME000017|ELME000120|PS00407,-
GJB2_HUMAN,C53R,0.961,Loss of Disulfide linkage at C53 (Pr = 0.38 | P = 6.1e-04); Altered Metal binding (Pr = 0.35 | P = 8.8e-03); Gain of Relative solvent accessibility (Pr = 0.33 | P = 3.3e-03); Altered Ordered interface (Pr = 0.31 | P = 0.01); Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Gain of Catalytic site at C53 (Pr = 0.16 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.5e-03), ELME000062|PS00407,-
GJB2_HUMAN,F142L,0.624,Gain of Helix (Pr = 0.33 | P = 1.4e-03); Loss of Strand (Pr = 0.30 | P = 2.2e-03), ELME000137|ELME000328,-
GJB2_HUMAN,V52L,0.170,-,-,-
GJB2_HUMAN,V52I,0.067,-,-,-
GJB2_HUMAN,V52T,0.156,-,-,-
GJB2_HUMAN,V13M,0.705,Altered Transmembrane protein (Pr = 0.32 | P = 7.3e-05); Loss of Relative solvent accessibility (Pr = 0.28 | P = 0.02), None,-
GJB2_HUMAN,I203K,0.908,, ELME000106,-
GJB2_HUMAN,I203T,0.603,, ELME000053|ELME000335,-
GJB2_HUMAN,E47K,0.871,Altered Transmembrane protein (Pr = 0.31 | P = 1.2e-04); Gain of Relative solvent accessibility (Pr = 0.29 | P = 0.01); Altered Metal binding (Pr = 0.26 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q48 (Pr = 0.12 | P = 7.5e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.04), None,-
GJB2_HUMAN,E47Q,0.800,Altered Transmembrane protein (Pr = 0.32 | P = 7.8e-05); Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Metal binding (Pr = 0.26 | P = 0.03); Loss of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Gain of Pyrrolidone carboxylic acid at E47 (Pr = 0.16 | P = 3.9e-03); Loss of Catalytic site at E47 (Pr = 0.09 | P = 0.05), None,-
GJB2_HUMAN,G109E,0.403,-,-,-
GJB2_HUMAN,V190D,0.922,Altered Transmembrane protein (Pr = 0.32 | P = 9.3e-05); Altered Ordered interface (Pr = 0.27 | P = 0.05); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Stability (Pr = 0.18 | P = 0.01); Altered Metal binding (Pr = 0.10 | P = 0.05), ELME000133|ELME000146|ELME000147,-
GJB2_HUMAN,K122I,0.526,Altered DNA binding (Pr = 0.33 | P = 1.3e-03); Altered Transmembrane protein (Pr = 0.17 | P = 0.01); Altered Coiled coil (Pr = 0.13 | P = 0.04), ELME000052|ELME000193|ELME000202,-
GJB2_HUMAN,K122R,0.169,-,-,-
GJB2_HUMAN,S17Y,0.891,Altered Ordered interface (Pr = 0.32 | P = 1.6e-03); Altered Transmembrane protein (Pr = 0.27 | P = 9.0e-04); Gain of Strand (Pr = 0.27 | P = 0.03); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Loss of Catalytic site at K22 (Pr = 0.16 | P = 0.02), ELME000120|ELME000182,-
GJB2_HUMAN,S17F,0.879,Altered Transmembrane protein (Pr = 0.28 | P = 4.0e-04); Gain of Strand (Pr = 0.26 | P = 0.04); Loss of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Loss of Catalytic site at K22 (Pr = 0.17 | P = 0.02), ELME000146,-
GJB2_HUMAN,L205P,0.954,, ELME000070|ELME000333,-
